ArticleBlood2013
EBV DNA: a Hodgkin lymphoma biomarker?
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Hodgkin lymphoma: the role of EBV plasma viral load testing in an HIV-endemic setting.Clinical and experimental medicine · 2024Article
- Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma.Blood advances · 2017Article
- Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Review
- The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.Journal of hematology & oncology · 2016Article
- Genome-wide Analysis of Epstein-Barr Virus (EBV) Integration and Strain in C666-1 and Raji Cells.Journal of Cancer · 2016Article
- Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.Hematology/oncology clinics of North America · 2014Review
- Clinical characteristics of 26 patients with primary extranodal Hodgkin lymphoma.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of Blood, Kanakry and colleagues report that increased pretreatment levels of plasma Epstein Barr virus DNA (EBV-DNA), as determined by quantitative real-time polymerase chain reaction (QRT-PCR), are associated with inferior outcomes among patients with previously untreated, advanced-stage Hodgkin lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.